

# Eric F. Morand

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6944571/publications.pdf>

Version: 2024-02-01

304  
papers

13,732  
citations

19657

61  
h-index

30922

102  
g-index

309  
all docs

309  
docs citations

309  
times ranked

13519  
citing authors

#	ARTICLE	IF	CITATIONS
1	Trial of Anifrolumab in Active Systemic Lupus Erythematosus. New England Journal of Medicine, 2020, 382, 211-221.	27.0	725
2	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Annals of the Rheumatic Diseases, 2014, 73, 958-967.	0.9	558
3	Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus. Nature Medicine, 2016, 22, 991-993.	30.7	457
4	Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Annals of the Rheumatic Diseases, 2016, 75, 1615-1621.	0.9	421
5	The BAFF/APRIL system in SLE pathogenesis. Nature Reviews Rheumatology, 2014, 10, 365-373.	8.0	338
6	MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nature Reviews Drug Discovery, 2006, 5, 399-411.	46.4	317
7	Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Annals of the Rheumatic Diseases, 2013, 72, 165-178.	0.9	315
8	Macrophage migration inhibitory factor in rheumatoid arthritis: Evidence of proinflammatory function and regulation by glucocorticoids. Arthritis and Rheumatism, 1999, 42, 1601-1608.	6.7	285
9	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Annals of the Rheumatic Diseases, 2017, 76, 554-561.	0.9	268
10	Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatology, The, 2019, 1, e208-e219.	3.9	250
11	Macrophage Migration Inhibitory Factor Induces Macrophage Recruitment via CC Chemokine Ligand 2. Journal of Immunology, 2006, 177, 8072-8079.	0.8	207
12	Stressâ€“glucocorticoidâ€“TSC22D3 axis compromises therapy-induced antitumor immunity. Nature Medicine, 2019, 25, 1428-1441.	30.7	185
13	A miR-19 regulon that controls NF-Î²B signaling. Nucleic Acids Research, 2012, 40, 8048-8058.	14.5	167
14	Modulation of inflammation and response to dexamethasone by Annexin 1 in antigenâ€“induced arthritis. Arthritis and Rheumatism, 2004, 50, 976-984.	6.7	149
15	Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis. Arthritis and Rheumatism, 1998, 41, 910-917.	6.7	144
16	Macrophage migration inhibitory factor is required for NLRP3 inflammasome activation. Nature Communications, 2018, 9, 2223.	12.8	142
17	Macrophage Migration Inhibitory Factor Deficiency Attenuates Macrophage Recruitment, Glomerulonephritis, and Lethality in MRL/lpr Mice. Journal of Immunology, 2006, 177, 5687-5696.	0.8	130
18	Neutrophil myeloperoxidase regulates T-cellâ€“driven tissue inflammation in mice by inhibiting dendritic cell function. Blood, 2013, 121, 4195-4204.	1.4	124

#	ARTICLE	IF	CITATIONS
19	Clinical associations of serum interleukin-17 in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2013, 15, R97.	3.5	122
20	Role of macrophage migration inhibitory factor (MIF) in murine antigen-induced arthritis: interaction with glucocorticoids. <i>Clinical and Experimental Immunology</i> , 2001, 123, 309-314.	2.6	117
21	Control of fibroblast-like synoviocyte proliferation by macrophage migration inhibitory factor. <i>Arthritis and Rheumatism</i> , 2003, 48, 103-109.	6.7	109
22	Role of GILZ in immune regulation, glucocorticoid actions and rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2011, 7, 340-348.	8.0	109
23	Macrophage migration inhibitory factor in rheumatoid arthritis: clinical correlations. <i>British Journal of Rheumatology</i> , 2002, 41, 558-562.	2.3	108
24	New therapeutic target in inflammatory disease: macrophage migration inhibitory factor. <i>Internal Medicine Journal</i> , 2005, 35, 419-426.	0.8	105
25	Regulation of synoviocyte phospholipase A2 and cyclooxygenase 2 by macrophage migration inhibitory factor. <i>Arthritis and Rheumatism</i> , 2001, 44, 1273-1280.	6.7	104
26	Annexin-1 Regulates Macrophage IL-6 and TNF via Glucocorticoid-Induced Leucine Zipper. <i>Journal of Immunology</i> , 2009, 183, 1435-1445.	0.8	104
27	Macrophage migration inhibitory factor in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2004, 31, 268-73.	2.0	104
28	Regulation of p53 by macrophage migration inhibitory factor in inflammatory arthritis. <i>Arthritis and Rheumatism</i> , 2003, 48, 1881-1889.	6.7	103
29	Macrophage migration inhibitory factor: A key cytokine in RA, SLE and atherosclerosis. <i>Clinica Chimica Acta</i> , 2009, 399, 1-7.	1.1	102
30	Brief Report: Interleukin-38 Exerts Antiinflammatory Functions and Is Associated With Disease Activity in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2015, 67, 3219-3225.	5.6	102
31	Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study. <i>Arthritis Research and Therapy</i> , 2017, 19, 62.	3.5	100
32	Deletion of macrophage migration inhibitory factor protects the heart from severe ischemia-reperfusion injury: A predominant role of anti-inflammation. <i>Journal of Molecular and Cellular Cardiology</i> , 2011, 50, 991-999.	1.9	99
33	The Role and Effects of Glucocorticoid-Induced Leucine Zipper in the Context of Inflammation Resolution. <i>Journal of Immunology</i> , 2015, 194, 4940-4950.	0.8	99
34	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021, 8, e000538.	2.7	97
35	Endogenous macrophage migration inhibitory factor modulates glucocorticoid sensitivity in macrophages via effects on MAP kinase phosphatase-1 and p38 MAP kinase. <i>FEBS Letters</i> , 2006, 580, 974-981.	2.8	93
36	Macrophage Migration Inhibitory Factor and CD74 Regulate Macrophage Chemotactic Responses via MAPK and Rho GTPase. <i>Journal of Immunology</i> , 2011, 186, 4915-4924.	0.8	90

#	ARTICLE	IF	CITATIONS
37	Macrophage Migration Inhibitory Factor Increases Leukocyte-Endothelial Interactions in Human Endothelial Cells via Promotion of Expression of Adhesion Molecules. <i>Journal of Immunology</i> , 2010, 185, 1238-1247.	0.8	89
38	Analysis of Serum Interleukin (IL)-1 <sup>2</sup> and IL-18 in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2018, 9, 1250.	4.8	89
39	Regulation of macrophage migration inhibitory factor by endogenous glucocorticoids in rat adjuvant-induced arthritis. <i>Arthritis and Rheumatism</i> , 2000, 43, 827.	6.7	88
40	Macrophage migration inhibitory factor regulates neutrophil chemotactic responses in inflammatory arthritis in mice. <i>Arthritis and Rheumatism</i> , 2011, 63, 960-970.	6.7	84
41	Loss of autophagy enhances MIF/macrophage migration inhibitory factor release by macrophages. <i>Autophagy</i> , 2016, 12, 907-916.	9.1	83
42	Inhibitory effect of annexin I on synovial inflammation in rat adjuvant arthritis. <i>Arthritis and Rheumatism</i> , 1999, 42, 1538-1544.	6.7	82
43	Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus. <i>Scientific Reports</i> , 2016, 6, 34604.	3.3	81
44	Glucocorticoid-induced leucine zipper is an endogenous antiinflammatory mediator in arthritis. <i>Arthritis and Rheumatism</i> , 2010, 62, 2651-2661.	6.7	80
45	Macrophage Migration Inhibitory Factor: A Therapeutic Target Across Inflammatory Diseases. <i>Inflammation and Allergy: Drug Targets</i> , 2007, 6, 183-190.	1.8	79
46	BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus. <i>Immunology and Cell Biology</i> , 2012, 90, 293-303.	2.3	79
47	Independent association of glucocorticoids with damage accrual in SLE. <i>Lupus Science and Medicine</i> , 2016, 3, e000157.	2.7	77
48	Regulation of IL-1 and TNF Receptor Expression and Function by Endogenous Macrophage Migration Inhibitory Factor. <i>Journal of Immunology</i> , 2006, 177, 4818-4825.	0.8	76
49	Critical role for macrophage migration inhibitory factor (MIF) in Ross River virus-induced arthritis and myositis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 12048-12053.	7.1	76
50	Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus. <i>Lupus</i> , 2013, 22, 873-884.	1.6	74
51	Annexin A1: potential for glucocorticoid sparing in RA. <i>Nature Reviews Rheumatology</i> , 2013, 9, 595-603.	8.0	73
52	Manipulation of B-cell responses with histone deacetylase inhibitors. <i>Nature Communications</i> , 2015, 6, 6838.	12.8	73
53	Mechanisms of Disease: macrophage migration inhibitory factor in SLE, RA and atherosclerosis. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 98-105.	3.2	72
54	Association of low vitamin D with high disease activity in an Australian systemic lupus erythematosus cohort. <i>Lupus Science and Medicine</i> , 2015, 2, e000064-e000064.	2.7	70

#	ARTICLE	IF	CITATIONS
55	Expression of mitogen-activated protein kinase phosphatase 1, a negative regulator of the mitogen-activated protein kinases, in rheumatoid arthritis: Up-regulation by interleukin-1? and glucocorticoids. <i>Arthritis and Rheumatism</i> , 2004, 50, 3118-3128.	6.7	69
56	Macrophage migration inhibitory factor: An emerging therapeutic target in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2003, 48, 291-299.	6.7	67
57	Macrophage migration inhibitory factor: a mediator of matrix metalloproteinase-2 production in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2006, 8, R132.	3.5	67
58	Macrophage migration inhibitory factor in rheumatoid arthritis. <i>Frontiers in Bioscience - Landmark</i> , 2005, 10, 12.	3.0	65
59	Association of Asian ethnicity with disease activity in SLE: an observational study from the Monash Lupus Clinic. <i>Lupus</i> , 2013, 22, 1425-1430.	1.6	65
60	MIF: Implications in the Pathoetiology of Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2015, 6, 577.	4.8	65
61	Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. <i>Lancet Rheumatology</i> , The, 2019, 1, e95-e102.	3.9	65
62	Abnormal hypothalamicâ€”pituitaryâ€”adrenal axis function in rheumatoid arthritis. Effects of nonsteroidal antiinflammatory drugs and water immersion. <i>Arthritis and Rheumatism</i> , 1994, 37, 1132-1137.	6.7	64
63	Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: <i>post-hoc</i> analysis of the Phase IIb MUSE trial of anifrolumab. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 706-713.	0.9	64
64	Antiinflammatory effect of lipocortin 1 in experimental arthritis. <i>Inflammation</i> , 1997, 21, 583-596.	3.8	61
65	Deficiency of Annexin A1 in CD4+ T Cells Exacerbates T Cellâ€”Dependent Inflammation. <i>Journal of Immunology</i> , 2013, 190, 997-1007.	0.8	61
66	Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis.. <i>Annals of the Rheumatic Diseases</i> , 1992, 51, 1318-1321.	0.9	59
67	Rediscovering MIF: New Tricks for an Old Cytokine. <i>Trends in Immunology</i> , 2019, 40, 447-462.	6.8	59
68	A formyl peptide receptor agonist suppresses inflammation and bone damage in arthritis. <i>British Journal of Pharmacology</i> , 2014, 171, 4087-4096.	5.4	58
69	Detection of Intracellular Lipocortin 1 in Human Leukocyte Subsets. <i>Clinical Immunology and Immunopathology</i> , 1995, 76, 195-202.	2.0	57
70	Macrophage migration inhibitory factor and glucocorticoid sensitivity. <i>Rheumatology</i> , 2006, 45, 937-943.	1.9	57
71	GILZ Overexpression Inhibits Endothelial Cell Adhesive Function through Regulation of NF-Î²B and MAPK Activity. <i>Journal of Immunology</i> , 2013, 191, 424-433.	0.8	57
72	Discordance of patient and physician health status concerns in systemic lupus erythematosus. <i>Lupus</i> , 2018, 27, 501-506.	1.6	57

#	ARTICLE	IF	CITATIONS
73	Reduction of arthritis severity in protease-activated receptor-deficient mice. Arthritis and Rheumatism, 2005, 52, 1325-1332.	6.7	54
74	Fibromyalgia Syndrome and Disease Activity in Systemic Lupus Erythematosus. Lupus, 1994, 3, 187-191.	1.6	53
75	Reperfusion-induced myocardial dysfunction is prevented by endogenous annexin A1 and its C-terminal derived peptide ANX1 <sub>226-242</sub> . British Journal of Pharmacology, 2013, 168, 238-252.	5.4	53
76	Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 629-633.	0.9	53
77	Differential roles of cardiac and leukocyte derived macrophage migration inhibitory factor in inflammatory responses and cardiac remodelling post myocardial infarction. Journal of Molecular and Cellular Cardiology, 2014, 69, 32-42.	1.9	52
78	Pro-Inflammatory Action of MIF in Acute Myocardial Infarction via Activation of Peripheral Blood Mononuclear Cells. PLoS ONE, 2013, 8, e76206.	2.5	51
79	Regulation of lung fibroblast activation by annexin A1. Journal of Cellular Physiology, 2013, 228, 476-484.	4.1	50
80	Divergent Effects of Endogenous and Exogenous Glucocorticoid-Induced Leucine Zipper in Animal Models of Inflammation and Arthritis. Arthritis and Rheumatism, 2013, 65, 1203-1212.	6.7	50
81	Endogenous Myeloperoxidase Is a Mediator of Joint Inflammation and Damage in Experimental Arthritis. Arthritis and Rheumatology, 2014, 66, 907-917.	5.6	49
82	Activation of synovial cell p38 MAP kinase by macrophage migration inhibitory factor. Journal of Rheumatology, 2004, 31, 1038-43.	2.0	49
83	Anti-neutrophil monoclonal antibody therapy inhibits the development of adjuvant arthritis. Clinical and Experimental Immunology, 1997, 107, 248-253.	2.6	48
84	Body composition in systemic lupus erythematosus. Rheumatology, 1998, 37, 514-519.	1.9	48
85	GILZ regulates Th17 responses and restrains IL-17-mediated skin inflammation. Journal of Autoimmunity, 2015, 61, 73-80.	6.5	47
86	Reduced arthritis in MIF deficient mice is associated with reduced T cell activation: down-regulation of ERK MAP kinase phosphorylation. Clinical and Experimental Immunology, 2008, 152, 372-380.	2.6	46
87	Genetic contributions to lupus nephritis in a multi-ethnic cohort of systemic lupus erythematosus patients. PLoS ONE, 2018, 13, e0199003.	2.5	46
88	Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study. Lancet Rheumatology, The, 2020, 2, e24-e30.	3.9	45
89	Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials. Lupus Science and Medicine, 2021, 8, e000464.	2.7	45
90	The Cytoplasmic Domain of Tissue Factor Contributes to Leukocyte Recruitment and Death in Endotoxemia. American Journal of Pathology, 2004, 165, 331-340.	3.8	44

#	ARTICLE	IF	CITATIONS
91	Annexin 1 Negatively Regulates IL-6 Expression via Effects on p38 MAPK and MAPK Phosphatase-1. Journal of Immunology, 2006, 177, 8148-8153.	0.8	44
92	Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort. Arthritis Research and Therapy, 2016, 18, 260.	3.5	44
93	Connexin-Dependent Transfer of cGAMP to Phagocytes Modulates Antiviral Responses. MBio, 2020, 11, .	4.1	44
94	Macrophage Migration Inhibitory Factor Inhibits the Antiinflammatory Effects of Glucocorticoids via Glucocorticoid-Induced Leucine Zipper. Arthritis and Rheumatology, 2014, 66, 2059-2070.	5.6	43
95	The need to define treatment goals for systemic lupus erythematosus. Nature Reviews Rheumatology, 2014, 10, 567-571.	8.0	43
96	Bcl-2 Antagonists Kill Plasmacytoid Dendritic Cells From Lupus-Prone Mice and Dampen Interferon- $\gamma$ Production. Arthritis and Rheumatology, 2015, 67, 797-808.	5.6	43
97	It hasn't gone away: the problem of glucocorticoid use in lupus remains. Rheumatology, 2016, 56, kew406.	1.9	43
98	Medical student psychological distress and academic performance. Medical Teacher, 2018, 40, 1257-1263.	1.8	43
99	Machine learning applied to whole-blood RNA-seq data uncovers distinct subsets of patients with systemic lupus erythematosus. Clinical and Translational Immunology, 2019, 8, e01093.	3.8	43
100	Glucocorticoid regulation of inflammation: The plot thickens. Inflammation Research, 1999, 48, 557-560.	4.0	42
101	Life table analysis of 879 treatment episodes with slow acting antirheumatic drugs in community rheumatology practice. Journal of Rheumatology, 1992, 19, 704-8.	2.0	42
102	Differential distribution of annexins-I, -II, -IV, and -VI in synovium.. Annals of the Rheumatic Diseases, 1995, 54, 841-845.	0.9	41
103	Macrophage Migration Inhibitory Factor Receptor CD74 Mediates Alphavirus-Induced Arthritis and Myositis in Murine Models of Alphavirus Infection. Arthritis and Rheumatism, 2013, 65, 2724-2736.	6.7	40
104	Glucocorticoid-Induced Leucine Zipper Governs the Therapeutic Potential of Mesenchymal Stem Cells by Inducing a Switch From Pathogenic to Regulatory Th17 Cells in a Mouse Model of Collagen-Induced Arthritis. Arthritis and Rheumatology, 2015, 67, 1514-1524.	5.6	40
105	Macrophage migration inhibitory factor is essential for osteoclastogenic mechanisms in vitro and in vivo mouse model of arthritis. Cytokine, 2015, 72, 135-145.	3.2	39
106	Impaired Glucocorticoid Induction of Mononuclear Leukocyte Lipocortin-1 in Rheumatoid Arthritis. Arthritis and Rheumatism, 1994, 37, 207-211.	6.7	38
107	The role of macrophage migration inhibitory factor in the inflammatory immune response and rheumatoid arthritis. Wiener Medizinische Wochenschrift, 2006, 156, 11-18.	1.1	38
108	Development of novel treatment strategies for inflammatory diseases—similarities and divergence between glucocorticoids and GILZ. Frontiers in Pharmacology, 2014, 5, 169.	3.5	38



#	ARTICLE	IF	CITATIONS
109	Endogenous Annexin-A1 Regulates Haematopoietic Stem Cell Mobilisation and Inflammatory Response Post Myocardial Infarction in Mice In Vivo. Scientific Reports, 2017, 7, 16615.	3.3	38
110	Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study. Lancet Rheumatology, The, 2019, 1, e103-e110.	3.9	38
111	Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Annals of the Rheumatic Diseases, 2022, 81, 951-961.	0.9	38
112	Hypothalamicâ€“pituitaryâ€“adrenal axis regulation of inflammation in rheumatoid arthritis. Immunology and Cell Biology, 2001, 79, 395-399.	2.3	37
113	Perspectives of Patients With Rheumatic Diseases in the Early Phase of <scp>COVID</scp>â€“19. Arthritis Care and Research, 2020, 72, 1189-1195.	3.4	37
114	Glucocorticoid-induced leucine zipper (GILZ) inhibits B cell activation in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2016, 75, 739-747.	0.9	36
115	Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. Lupus, 2021, 30, 1254-1263.	1.6	36
116	Three year follow-up of body composition changes in pre-menopausal women with systemic lupus erythematosus. Rheumatology, 1999, 38, 59-65.	1.9	35
117	MAPK phosphatases as novel targets for rheumatoid arthritis. Expert Opinion on Therapeutic Targets, 2008, 12, 795-808.	3.4	35
118	Association of MIF, but not type I interferon-induced chemokines, with increased disease activity in Asian patients with systemic lupus erythematosus. Scientific Reports, 2016, 6, 29909.	3.3	35
119	Pregnancy outcome in systemic lupus erythematosus (SLE): a review of 54 cases. Australian and New Zealand Journal of Medicine, 1998, 28, 18-22.	0.5	34
120	Formyl peptide receptor activation inhibits the expansion of effector T cells and synovial fibroblasts and attenuates joint injury in models of rheumatoid arthritis. International Immunopharmacology, 2018, 61, 140-149.	3.8	34
121	Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials. Lancet Rheumatology, The, 2022, 4, e282-e292.	3.9	34
122	Endogenous glucocorticoids modulate neutrophil migration and synovial P-selectin but not neutrophil phagocytic or oxidative function in experimental arthritis. Clinical and Experimental Immunology, 1998, 112, 383-388.	2.6	33
123	Fibroblasts and synovial immunity. Current Opinion in Pharmacology, 2013, 13, 565-569.	3.5	33
124	Vitamin D and systemic lupus erythematosus: continued evolution. International Journal of Rheumatic Diseases, 2015, 18, 242-249.	1.9	33
125	Attainment of treat-to-target endpoints in SLE patients with high disease activity in the ataccept phase 2b ADDRESS II study. Rheumatology, 2020, 59, 2930-2938.	1.9	33
126	Glucocorticoid inhibition of adjuvant arthritis synovial macrophage nitric oxide production: role of lipocortin 1. Clinical and Experimental Immunology, 1998, 111, 117-122.	2.6	32



#	ARTICLE	IF	CITATIONS
127	Reduction in Arthritis Severity and Modulation of Immune Function in Tissue Factor Cytoplasmic Domain Mutant Mice. American Journal of Pathology, 2004, 164, 109-117.	3.8	32
128	Comparison of performance of specific (SLEQOL) and generic (SF36) health-related quality of life questionnaires and their associations with disease status of systemic lupus erythematosus: a longitudinal study. Arthritis Research and Therapy, 2020, 22, 8.	3.5	32
129	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Science and Medicine, 2021, 8, e000590.	2.7	31
130	Targeting the side effects of steroid therapy in autoimmune diseases: the role of GILZ. Discovery Medicine, 2012, 13, 123-33.	0.5	30
131	Effects of glucocorticoids on inflammation and arthritis. Current Opinion in Rheumatology, 2007, 19, 302-307.	4.3	29
132	Glucocorticoid-Induced Leucine Zipper (GILZ) Regulates Testicular FOXO1 Activity and Spermatogonial Stem Cell (SSC) Function. PLoS ONE, 2013, 8, e59149.	2.5	29
133	Methotrexate use in systemic lupus erythematosus. Lupus, 1997, 6, 385-389.	1.6	27
134	The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus. Lancet Rheumatology, The, 2021, 3, e517-e531.	3.9	26
135	Suppression of adjuvant arthritis and synovial macrophage inducible nitric oxide by N-iminoethyl-L-ornithine, a nitric oxide synthase inhibitor. Inflammation, 1997, 21, 299-311.	3.8	25
136	GILZ: Glitzing up our understanding of the glucocorticoid receptor in psychopathology. Brain Research, 2014, 1574, 60-69.	2.2	25
137	The Australian Lupus Registry and Biobank: a timely initiative. Medical Journal of Australia, 2017, 206, 194-195.	1.7	25
138	GILZ-dependent modulation of mTORC1 regulates spermatogonial maintenance. Development (Cambridge), 2018, 145, .	2.5	25
139	Analysis of serum B cell-activating factor from the tumor necrosis factor family (<scp>BAFF</scp>) and its soluble receptors in systemic lupus erythematosus. Clinical and Translational Immunology, 2019, 8, e01047.	3.8	25
140	SARS-COV-2 vaccine acceptance in patients with rheumatic diseases: a cross-sectional study. Human Vaccines and Immunotherapeutics, 2021, 17, 4048-4056.	3.3	25
141	The tumour suppressor gene p53 modulates the severity of antigen-induced arthritis and the systemic immune response. Clinical and Experimental Immunology, 2008, 152, 345-353.	2.6	24
142	Treat to target, remission and low disease activity in SLE. Best Practice and Research in Clinical Rheumatology, 2017, 31, 342-350.	3.3	24
143	Cardiovascular risk profiles in a lupus cohort: what do different calculators tell us?. Lupus Science and Medicine, 2017, 4, e000212.	2.7	24
144	Development of the Asia Pacific Lupus Collaboration cohort. International Journal of Rheumatic Diseases, 2019, 22, 425-433.	1.9	24

#	ARTICLE	IF	CITATIONS
145	Divergent effects of acute versus chronic glucocorticoids in COVID-19. <i>Lancet Rheumatology</i> , The, 2021, 3, e168-e170.	3.9	24
146	Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis. <i>Lupus Science and Medicine</i> , 2022, 9, e000625.	2.7	24
147	Endogenous estrogen regulation of inflammatory arthritis and cytokine expression in male mice, predominantly via estrogen receptor $\alpha$ . <i>Arthritis and Rheumatism</i> , 2010, 62, 1017-1025.	6.7	23
148	Focus on systemic lupus erythematosus in Indigenous Australians: towards a better understanding of autoimmune diseases. <i>Internal Medicine Journal</i> , 2013, 43, 227-234.	0.8	23
149	Longitudinal association of type 1 interferon-induced chemokines with disease activity in systemic lupus erythematosus. <i>Scientific Reports</i> , 2018, 8, 3268.	3.3	23
150	Effect of storage duration on cytokine stability in human serum and plasma. <i>Cytokine</i> , 2019, 113, 453-457.	3.2	23
151	High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2020, 7, e000372.	2.7	23
152	IDIOPATHIC POLYMYOSITIS COMPLICATED BY ARTHRITIS AND MESANGIAL PROLIFERATIVE GLOMERULONEPHRITIS: CASE REPORT AND REVIEW OF THE LITERATURE. <i>Rheumatology</i> , 1993, 32, 929-931.	1.9	22
153	Independent roles of Macrophage Migration Inhibitory Factor and endogenous, but not exogenous glucocorticoids in regulating leukocyte trafficking. <i>Microcirculation</i> , 2009, 16, 735-748.	1.8	22
154	Glucocorticoid-induced leucine zipper modulates macrophage polarization and apoptotic cell clearance. <i>Pharmacological Research</i> , 2020, 158, 104842.	7.1	22
155	Is macrophage migration inhibitory factor a therapeutic target in systemic lupus erythematosus?. <i>Immunology and Cell Biology</i> , 2003, 81, 367-373.	2.3	21
156	Identification of NURR1 as a Mediator of MIF Signaling During Chronic Arthritis. <i>American Journal of Pathology</i> , 2010, 177, 2366-2378.	3.8	21
157	Australian ethnicity in systemic lupus erythematosus: an Australian perspective. <i>Internal Medicine Journal</i> , 2013, 43, 618-624.	0.8	21
158	Disseminated Enteroviral Infection Associated with Obinutuzumab. <i>Emerging Infectious Diseases</i> , 2015, 21, 1661-1663.	4.3	21
159	Optimizing the use of existing therapies in lupus. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 129-137.	1.9	21
160	Identification of a novel cell type-specific intronic enhancer of macrophage migration inhibitory factor (MIF) and its regulation by mithramycin. <i>Clinical and Experimental Immunology</i> , 2011, 163, 178-188.	2.6	20
161	Inhibition of TNF-induced IL-6 by the TWEAK-Fn14 interaction in rheumatoid arthritis fibroblast like synoviocytes. <i>Cellular Immunology</i> , 2012, 272, 293-298.	3.0	20
162	Laboratory investigation results influence Physician's Global Assessment (PGA) of disease activity in SLE. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 787-792.	0.9	20

#	ARTICLE	IF	CITATIONS
163	Enhanced induction of LPS-induced fibroblast MCP-1 by interferon- $\gamma$ : Involvement of JNK and MAPK phosphatase-1. <i>Cellular Immunology</i> , 2009, 255, 26-32.	3.0	19
164	Remission in SLE: closing in on the target. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2103-2106.	0.9	19
165	Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2020, 72, 1289-1295.	3.4	19
166	Does expert opinion match the operational definition of the Lupus Low Disease Activity State (LLDAS)? A case-based construct validity study. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 798-803.	3.4	18
167	Annexin I surface binding sites and their regulation on human fibroblast-like synoviocytes. <i>Arthritis and Rheumatism</i> , 2000, 43, 2537-2542.	6.7	17
168	IL-18 is redundant in T-cell responses and in joint inflammation in antigen-induced arthritis. <i>Immunology and Cell Biology</i> , 2006, 84, 166-173.	2.3	17
169	Regulation of Annexin I in Rheumatoid Synovial Cells by Glucocorticoids and Interleukin-1. <i>Mediators of Inflammation</i> , 2006, 2006, 1-6.	3.0	17
170	Validation of the Lupus Impact Tracker in an Australian patient cohort. <i>Lupus</i> , 2017, 26, 98-105.	1.6	17
171	Could GILZ Be the Answer to Glucocorticoid Toxicity in Lupus?. <i>Frontiers in Immunology</i> , 2019, 10, 1684.	4.8	17
172	Exacerbation of adjuvant arthritis by adrenalectomy is associated with reduced leukocyte lipocortin 1. <i>Journal of Rheumatology</i> , 1997, 24, 1758-64.	2.0	17
173	"Not at target": prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study. <i>Arthritis Research and Therapy</i> , 2022, 24, 70.	3.5	17
174	Physician Global Assessment International Standardisation CONsensus in Systemic Lupus Erythematosus: the PISCOS study. <i>Lancet Rheumatology</i> , The, 2022, 4, e441-e449.	3.9	17
175	Annexin I and dexamethasone effects on phospholipase and cyclooxygenase activity in human synoviocytes. <i>Mediators of Inflammation</i> , 2000, 9, 125-132.	3.0	16
176	Glucocorticoid-Induced Leucine Zipper Protein Controls Macropinocytosis in Dendritic Cells. <i>Journal of Immunology</i> , 2016, 197, 4247-4256.	0.8	16
177	Urinary B-cell-activating factor of the tumour necrosis factor family (BAFF) in systemic lupus erythematosus. <i>Lupus</i> , 2018, 27, 2029-2040.	1.6	16
178	Outcomes of patients admitted to hospital medical units with back pain. <i>Internal Medicine Journal</i> , 2019, 49, 316-322.	0.8	16
179	Rare variants in non-coding regulatory regions of the genome that affect gene expression in systemic lupus erythematosus. <i>Scientific Reports</i> , 2019, 9, 15433.	3.3	16
180	Analysis of serum interleukin-1 $\beta$ , IL-1 $\beta$ and IL-18 in patients with systemic sclerosis. <i>Clinical and Translational Immunology</i> , 2019, 8, e1045.	3.8	16

#	ARTICLE	IF	CITATIONS
181	Sequence-dependent inhibition of cGAS and TLR9 DNA sensing by 2- <i>O</i> -methyl gapmer oligonucleotides. <i>Nucleic Acids Research</i> , 2021, 49, 6082-6099.	14.5	16
182	Stress and the onset of SLE. <i>Nature Reviews Rheumatology</i> , 2018, 14, 127-128.	8.0	15
183	Global consensus building and prioritisation of fundamental lupus challenges: the ALPHA project. <i>Lupus Science and Medicine</i> , 2019, 6, e000342.	2.7	15
184	A potential association between IL-6 and type I and III interferons in systemic lupus erythematosus. <i>Clinical and Translational Immunology</i> , 2019, 8, e01097.	3.8	15
185	Utility of repeated antinuclear antibody tests: a retrospective database study. <i>Lancet Rheumatology</i> , The, 2020, 2, e412-e417.	3.9	15
186	Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2020, 7, e000375.	2.7	15
187	Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2022, 61, 4752-4762.	1.9	15
188	Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 962-969.	0.9	15
189	Corticosteroids in the treatment of rheumatologic diseases. <i>Current Opinion in Rheumatology</i> , 2000, 12, 171-177.	4.3	14
190	Analysis of serum macrophage migration inhibitory factor and Dopachrome tautomerase in systemic sclerosis. <i>Clinical and Translational Immunology</i> , 2018, 7, e1042.	3.8	14
191	Associations of metabolic syndrome in SLE. <i>Lupus Science and Medicine</i> , 2020, 7, e000436.	2.7	14
192	Glucocorticoid gene signatures in systemic lupus erythematosus and the effects of type I interferon: a cross-sectional and in-vitro study. <i>Lancet Rheumatology</i> , The, 2021, 3, e357-e370.	3.9	14
193	Necrotic cell death increases the release of macrophage migration inhibitory factor by monocytes/macrophages. <i>Immunology and Cell Biology</i> , 2020, 98, 782-790.	2.3	13
194	Clinician-reported outcome measures in lupus trials: a problem worth solving. <i>Lancet Rheumatology</i> , The, 2021, 3, e595-e603.	3.9	13
195	Characteristics of azathioprine use and cessation in a longitudinal lupus cohort. <i>Lupus Science and Medicine</i> , 2015, 2, e000105.	2.7	12
196	Acceptability of opt-out consent in a hospital patient population. <i>Internal Medicine Journal</i> , 2018, 48, 84-87.	0.8	12
197	Gilz-Activin A as a Novel Signaling Axis Orchestrating Mesenchymal Stem Cell and Th17 Cell Interplay. <i>Theranostics</i> , 2018, 8, 846-859.	10.0	12
198	COVID-19 infection in patients with systemic lupus erythematosus: Data from the Asia Pacific Lupus Collaboration. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 1255-1257.	1.9	12

#	ARTICLE	IF	CITATIONS
199	The impact of telerheumatology and COVID-19 on outcomes in a tertiary rheumatology service: a retrospective audit. <i>Rheumatology</i> , 2021, 60, 3478-3480.	1.9	12
200	What Does it Mean to be a British Isles Lupus Assessment Groupâ€‘Based Composite Lupus Assessment Responder? Post Hoc Analysis of 2 Phase 3 Trials. <i>Arthritis and Rheumatology</i> , 2021, 73, 2059-2068.	5.6	12
201	SCLEROTHERAPY AS TREATMENT OF RECURRENT BLEEDING FROM UPPER GASTROINTESTINAL TELANGIECTASIA IN CREST SYNDROME. <i>Rheumatology</i> , 1993, 32, 760-761.	1.9	11
202	Corticosteroids in the treatment of rheumatologic diseases. <i>Current Opinion in Rheumatology</i> , 1998, 10, 179-183.	4.3	11
203	Remission in SLE â€” are we there yet?. <i>Nature Reviews Rheumatology</i> , 2016, 12, 696-698.	8.0	11
204	Algorithm for calculating high disease activity in SLE. <i>Rheumatology</i> , 2021, 60, 4291-4297.	1.9	11
205	Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 5379-5389.	1.9	11
206	Prevention of infective complications in systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 880-895.	1.9	11
207	Endogenous glucocorticoids modulate experimental anti-glomerular basement membrane glomerulonephritis. <i>Clinical and Experimental Immunology</i> , 2000, 119, 161-168.	2.6	10
208	Analysis of urinary macrophage migration inhibitory factor in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2018, 5, e000277.	2.7	10
209	Who is afraid of biosimilars? Openness to biosimilars in an Australian cohort of patients with rheumatoid arthritis. <i>Internal Medicine Journal</i> , 2020, 50, 374-377.	0.8	10
210	OP0296â€‘...THE 2021 DORIS DEFINITION OF REMISSION IN SLE â€” FINAL RECOMMENDATIONS FROM AN INTERNATIONAL TASK FORCE. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 181.1-182.	0.9	10
211	Determinants and protective associations of the lupus low disease activity state in a prospective Chinese cohort. <i>Clinical Rheumatology</i> , 2022, 41, 357-366.	2.2	10
212	Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2022, 61, 1900-1910.	1.9	10
213	GLUCOCORTICOIDS IN RHEUMATOID ARTHRITISâ€”MEDIATORS AND MECHANISMS. <i>Rheumatology</i> , 1993, 32, 816-819.	1.9	9
214	Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational <i>study</i>. <i>Rheumatology</i> , 2021, 60, 5185-5193.	1.9	9
215	OP0049â€‘...EFFICACY OF ANIFROLUMAB IN ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: PATIENT SUBGROUP ANALYSIS OF BICLA RESPONSE IN 2 PHASE 3 TRIALS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 32-32.	0.9	9
216	Churg-Strauss syndrome: the use of cyclophosphamide in mononeuritis. <i>British Journal of Rheumatology</i> , 2003, 42, 390-391.	2.3	8

#	ARTICLE	IF	CITATIONS
217	Lower level of synovial fluid interferon- $\gamma$ in HLA-B27-positive than in HLA-B27-negative patients with Chlamydia trachomatis reactive arthritis. British Journal of Rheumatology, 2003, 43, 249-250.	2.3	8
218	Breaking the chain of transmission within a tertiary health service: An approach to contact tracing during the COVID-19 pandemic. Infection, Disease and Health, 2021, 26, 118-122.	1.1	8
219	Evaluation of the Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in SLE. Lupus Science and Medicine, 2021, 8, e000580.	2.7	8
220	Lymphocytes from systemic lupus erythematosus patients display increased spreading on VCAM-1, an effect associated with active renal involvement. Lupus, 2012, 21, 632-641.	1.6	7
221	Successes, challenges and developments in Australian rheumatology. Nature Reviews Rheumatology, 2015, 11, 430-436.	8.0	7
222	Identification of a novel autoantibody against self-vimentin specific in secondary Sjögren's syndrome. Arthritis Research and Therapy, 2018, 20, 30.	3.5	7
223	The ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and research. Lupus Science and Medicine, 2021, 8, e000433.	2.7	7
224	GILZ Regulates the Expression of Pro-Inflammatory Cytokines and Protects Against End-Organ Damage in a Model of Lupus. Frontiers in Immunology, 2021, 12, 652800.	4.8	7
225	Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab. Lancet Rheumatology, The, 2022, 4, e198-e207.	3.9	7
226	Fibromyalgia, mood disorders, cognitive test results, cognitive symptoms and quality of life in systemic lupus erythematosus. Rheumatology, 2022, 62, 190-199.	1.9	7
227	Evaluating the Construct of Damage in Systemic Lupus Erythematosus. Arthritis Care and Research, 2023, 75, 998-1006.	3.4	7
228	Urinary excretion of the pyridinium cross-links of collagen in systemic lupus erythematosus. Clinical Rheumatology, 1998, 17, 271-276.	2.2	6
229	GILZ: a new link between the hypothalamic pituitary adrenal axis and rheumatoid arthritis?. Immunology and Cell Biology, 2014, 92, 747-751.	2.3	6
230	Quality of Care for Systemic Lupus Erythematosus: Mind the Knowledge Gap. Journal of Rheumatology, 2017, 44, 271-278.	2.0	6
231	Treat-to-target Endpoint Definitions in Systemic Lupus Erythematosus: More Is Less?. Journal of Rheumatology, 2019, 46, 1256-1258.	2.0	6
232	Treatment Update in Systemic Lupus Erythematosus. Rheumatic Disease Clinics of North America, 2021, 47, 513-530.	1.9	6
233	Patterns of Medication Use in Systemic Lupus Erythematosus: A Multicenter Cohort Study. Arthritis Care and Research, 2022, 74, 2033-2041.	3.4	6
234	Medical problems in joint replacement patients: a retrospective study of 243 total hip arthroplasties. Medical Journal of Australia, 1990, 152, 408-413.	1.7	6

#	ARTICLE	IF	CITATIONS
235	Single anticardiolipin measurement in the routine management of patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 1994, 21, 91-3.	2.0	6
236	Modulation of expression and cellular distribution of p21 by macrophage migration inhibitory factor. <i>Journal of Inflammation</i> , 2009, 6, 24.	3.4	5
237	Genetic variants in the human glucocorticoid-induced leucine zipper (<i><scp>GILZ</scp></i>) gene in fertile and infertile men. <i>Andrology</i> , 2013, 1, 451-455.	3.5	5
238	Severe infections remain common in a real-world rheumatoid arthritis cohort: A simple clinical model to predict infection risk. , 2021, 8, 133-138.		5
239	GILZ regulates type I interferon release and sequesters STAT1. <i>Journal of Autoimmunity</i> , 2022, 131, 102858.	6.5	5
240	Lack of involvement of lipocortin 1 in dexamethasone suppression of IL-1 release. <i>Mediators of Inflammation</i> , 1993, 2, 49-52.	3.0	4
241	Advances in the understanding of neuroendocrine function in rheumatic disease. <i>Australian and New Zealand Journal of Medicine</i> , 1996, 26, 543-551.	0.5	4
242	Corticosteroids in the treatment of rheumatologic diseases. <i>Current Opinion in Rheumatology</i> , 1997, 9, 200-205.	4.3	4
243	ARA Scientific Posters. <i>Internal Medicine Journal</i> , 2012, 42, 9-35.	0.8	4
244	Serum and urinary macrophage migration inhibitory factor (MIF) in primary Sjögren's syndrome. <i>Joint Bone Spine</i> , 2019, 86, 393-395.	1.6	4
245	Novel Methods of Incorporating Time in Longitudinal Multivariate Analysis Reveals Hidden Associations With Disease Activity in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2019, 10, 1649.	4.8	4
246	Response to: "Comment on: "Lupus Low Disease Activity State(LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab"™ by Eric Morand et al"™ by Isenberg. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e122-e122.	0.9	4
247	Temporal Analysis of Brd4 Displacement in the Control of B Cell Survival, Proliferation, and Differentiation. <i>Cell Reports</i> , 2020, 33, 108290.	6.4	4
248	Systemic Lupus Erythematosus Outcome Measures for Systemic Lupus Erythematosus Clinical Trials. <i>Rheumatic Disease Clinics of North America</i> , 2021, 47, 415-426.	1.9	4
249	Measurement of specific organ domains in lupus randomized controlled trials: a scoping review. <i>Rheumatology</i> , 2022, 61, 1341-1353.	1.9	4
250	Cognitive dysfunction in systemic lupus erythematosus: how do we advance our understanding?. <i>Lancet Rheumatology</i> , The, 2022, , .	3.9	4
251	Glucocorticoid-Induced Leucine Zipper Alleviates Lung Inflammation and Enhances Bacterial Clearance during Pneumococcal Pneumonia. <i>Cells</i> , 2022, 11, 532.	4.1	4
252	Smooth muscle myopathy as an underrecognized manifestation of active systemic lupus erythematosus. <i>Internal Medicine Journal</i> , 2011, 41, 495-498.	0.8	3



#	ARTICLE	IF	CITATIONS
253	New answers to old problems. Nature Reviews Rheumatology, 2016, 12, 73-74.	8.0	3
254	POS0688â€¦CHARACTERIZATION OF PK/PD OF ANIFROLUMAB IN PATIENTS WITH MODERATE TO SEVERE SLE. Annals of the Rheumatic Diseases, 2021, 80, 590-591.	0.9	3
255	Disease course following High Disease Activity Status revealed patterns in SLE. Arthritis Research and Therapy, 2021, 23, 191.	3.5	3
256	The Efficacy and Safety of Anifrolumab in Japanese Patients With Systemic Lupus Erythematosus: TULIP-2 Subanalysis. Modern Rheumatology, 2022, , .	1.8	3
257	Combination therapy with methotrexate and sulphasalazine in rheumatoid arthritis--tolerance of therapy.. Annals of the Rheumatic Diseases, 1994, 53, 703-703.	0.9	2
258	Therapeutic opportunities for antagonism of macrophage migration inhibitory factor. Expert Opinion on Therapeutic Patents, 2003, 13, 1189-1212.	5.0	2
259	A1.38â€¦Mesenchymal stem cells induce non-classical IL-10-producing regulatory TH17 cells in arthritis: role of gilz. Annals of the Rheumatic Diseases, 2014, 73, A16.2-A16.	0.9	2
260	A8.11â€¦gilz-dependent activin a production by MSC inhibits TH17 differentiation. Annals of the Rheumatic Diseases, 2014, 73, A80.2-A80.	0.9	2
261	Establishing Consensus Understanding of the Barriers to Drug Development in Lupus. Therapeutic Innovation and Regulatory Science, 2020, 54, 1159-1165.	1.6	2
262	Systemic lupus erythematosus: a clinical update. Internal Medicine Journal, 2021, 51, 1219-1228.	0.8	2
263	Regulation of synoviocyte phospholipase A2 and cyclooxygenase 2 by macrophage migration inhibitory factor. , 2001, 44, 1273.		2
264	Assays for Inducing and Measuring Cell Death to Detect Macrophage Migration Inhibitory Factor (MIF) Release. Methods in Molecular Biology, 2020, 2080, 173-183.	0.9	2
265	The Anti-Inflammatory Role of Annexin-1 in Arthritis. Current Rheumatology Reviews, 2006, 2, 325-331.	0.8	1
266	Evidence for the role of CD74 in innate immunity, arthritis, and the action of migration inhibitory factor. Arthritis Research and Therapy, 2007, 9, P25.	3.5	1
267	THU0298â€¦Consensus Definition of a Low Disease Activity State in Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases, 2013, 72, A267.1-A267.	0.9	1
268	Plasmacytoid dendritic cells from parent strains of the NZB/W F1 lupus mouse contribute different characteristics to autoimmune propensity. Immunology and Cell Biology, 2020, 98, 203-214.	2.3	1
269	Routine testing for hyposplenism in a lupus clinic diagnoses; new cases and opportunities for intervention. Lupus, 2021, 30, 687-688.	1.6	1
270	What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts. Lupus Science and Medicine, 2021, 8, e000506.	2.7	1

#	ARTICLE	IF	CITATIONS
271	Impact of COVID-19 telehealth on outpatient test completion. Internal Medicine Journal, 2021, 51, 1614-1618.	0.8	1
272	Associations between physicians' global assessment of disease activity and patient-reported outcomes in patients with systemic lupus erythematosus: A longitudinal study. Lupus, 2021, 30, 1586-1595.	1.6	1
273	Serum soluble Fas and Fas ligand (FasL) in primary Sjögren's syndrome. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 254-256.	0.8	1
274	Easy-BILAG: as easy as ABC?. Rheumatology, 2022, 61, 3879-3880.	1.9	1
275	The Relationship between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus. Journal of Clinical Pharmacology, 2022, , .	2.0	1
276	Investigating immunoregulatory effects of myeloid cell autophagy in acute and chronic inflammation. Immunology and Cell Biology, 2022, 100, 605-623.	2.3	1
277	BSR Poster Session a. Rheumatology, 1993, 32, 3-88.	1.9	0
278	Rheumatology. Medical Journal of Australia, 2002, 176, 41-41.	1.7	0
279	Title is missing!. Arthritis Research, 2003, 5, 127.	2.0	0
280	Inflammatory Arthritis. , 2007, , 229-255.		0
281	276 Annexin-1 regulates cytokines and dexamethasone sensitivity via glucocorticoid-induced leucine zipper. Cytokine, 2008, 43, 309.	3.2	0
282	Correction: Macrophage Migration Inhibitory Factor Increases Leukocyte-Endothelial Interactions in Human Endothelial Cells via Promotion of Expression of Adhesion Molecules. Journal of Immunology, 2010, 185, 4959-4959.	0.8	0
283	Erratum to "Differential roles of cardiac and leukocyte derived macrophage migration inhibitory factor in inflammatory responses and cardiac remodelling post myocardial infarction" [J Mol Cell Cardiol 69 (2014) 32-42]. Journal of Molecular and Cellular Cardiology, 2014, 75, 198.	1.9	0
284	Macrophage migration inhibitory factor. Aids, 2014, 28, 1693-1694.	2.2	0
285	Infections and musculoskeletal conditions. Best Practice and Research in Clinical Rheumatology, 2015, 29, 187-188.	3.3	0
286	Editorial: Focus on Systemic Lupus Erythematosus. Frontiers in Immunology, 2016, 7, 400.	4.8	0
287	Defining remission in systemic lupus erythematosus: still elusive?. Lancet Rheumatology, The, 2019, 1, e137-e138.	3.9	0
288	OP0246...ATTAINMENT OF THE LUPUS LOW DISEASE ACTIVITY STATE IS ASSOCIATED WITH PROTECTION FROM DAMAGE ACCRUAL IN PATIENTS WITH ACTIVE DISEASE AT BASELINE. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
289	OP0020â€¦LESS IS MORE: ANA-LYSING THE IMPACT OF REPEATED ANTINUCLEAR ANTIBODY TESTING. , 2019, , .		0
290	OP0330â€¦#X00A0; COMPARISON OF THE EFFECTS OF DORIS REMISSION AND LUPUS LOW DISEASE ACTIVITY STATE (LLDAS) ON DISEASE OUTCOMES IN A MULTINATIONAL PROSPECTIVE STUDY. , 2019, , .		0
291	THU0253â€¦EFFECT OF GLUCOCORTICOIDS ON DAMAGE ACCRUAL IN SLE PATIENTS WITH NO CLINICAL OR SEROLOGICAL DISEASE ACTIVITY. , 2019, , .		0
292	AB0539â€¦TEN YEARS OF THE MONASH LUPUS CLINIC: INSIGHT INTO THE CHARACTERISTICS AND OUTCOMES OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS IN AUSTRALIA. , 2019, , .		0
293	Systemic Glucocorticoid Therapy for SLE. , 2019, , 661-672.		0
294	Interferon blockade in systemic lupus erythematosus: Light at the end of the tunnel for novel therapies for lupus?. International Journal of Rheumatic Diseases, 2020, 23, 995-997.	1.9	0
295	Response to: â€œPhysician global assessment in systemic lupus erythematosus: can we rely on its reliability?â€™ by Chessa et al. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2020-217692.	0.9	0
296	Glucocorticoids. , 2021, , 611-622.		0
297	MIF antagonism restores corticosteroid sensitivity in a murine model of severe asthma. , 2018, , .		0
298	Response to: â€œPhysician's global assessment is often useful in SLE, but not always: the case of clinical remissionâ€™ by Zenet al. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2020-217687.	0.9	0
299	AB0376â€¦DETERMINANTS AND PROTECTIVE EFFECTS OF A LOW DISEASE ACTIVITY STATE IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM A PROSPECTIVE CHINESE COHORT. Annals of the Rheumatic Diseases, 2020, 79, 1488-1489.	0.9	0
300	Filgotinib in cutaneous lupus: is a negative positive?. Rheumatology, 2021, , .	1.9	0
301	Connective tissue disease: an approach. Australian Family Physician, 1993, 22, 2107-11.	0.5	0
302	Regulation of Glucocorticoid Sensitivity by Macrophage Migration Inhibitory Factor. , 0, , 145-161.		0
303	Association of clinic setting with quality indicator performance in systemic lupus erythematosus: a cross-sectional study. Arthritis Research and Therapy, 2022, 24, .	3.5	0
304	Comparisons between US norm-based two-component and Japanese norm-based three-component SF-36 summary scores in systemic lupus erythematosus patients. Modern Rheumatology, 0, , .	1.8	0